WI-ROCKWELL-AUTOMATION
23.4.2018 14:02:11 CEST | Business Wire | Press release
Industrial organizations must be able to quickly identify ways to tighten production schedules and maximize revenue. Gaining insight into operations and production capabilities to make informed decisions has often involved time-intensive IT projects and a highly specialized skillset. Today, Rockwell Automation expands the FactoryTalk® Analytics portfolio, a robust advanced analytics environment that empowers users with the ability to quickly and confidently make informed decisions. These latest advancements were developed to reduce the complexity of the operations environment for manufacturers and producers and their employees who are driving operations.
FactoryTalk Analytics has been developed for scale, discovering and connecting data sources from the edge of the network up through the enterprise, and then intelligently fusing the information to resolve issues close to the source. At the edge or the device, this can result in near-immediate resolution of production issues. Empowered with machine learning capabilities, FactoryTalk Analytics learns the process and looks for trends in the data, proactively presenting users with insights before an issue arises.
FactoryTalk Analytics brings contemporary user experience capabilities, which are common for consumer experiences, to the production environment. Focused on driving ease of use and productivity, FactoryTalk Analytics features internet-like search capabilities of production data, as well as self-serve drill-downs, allowing the user to make data-driven decisions quickly.
Rockwell Automation has chosen the Microsoft® Azure™ cloud as the preferred platform for FactoryTalk Analytics, to help develop and power advanced IoT solutions from the edge to the cloud.
Rockwell Automation executed several customer pilots before the official release of FactoryTalk Analytics, which generated several purpose-driven applications that prioritize ease of use and faster time to value.
In one pilot, a manufacturer of solar panels used FactoryTalk Analytics to connect the data sources of legacy systems spread across multiple facilities. They’re now able to more efficiently manage data both on-premise and in the cloud, which will minimize downtime and allow them to save millions of dollars in IT spend.
In another pilot, a global automotive manufacturer implemented FactoryTalk Analytics to help improve operational productivity. Purpose-driven applications brought data together from disparate systems that had previously proven difficult to integrate and had limited workers’ ability to investigate production issues. The solution is giving production managers and executives new visibility into key areas of operations and helping them more accurately forecast production targets.
“Smart manufacturing promises to remove blind spots between organizational silos, putting users directly in touch with information,” said Blake Moret, Chairman and Chief Executive Officer, Rockwell Automation. “Our deep experience in production applications, coupled with technology that integrates control and information, provides outcomes of increased productivity for both existing and greenfield sites. Importantly, our partners are taking advantage of these solutions to enhance the value of their own offerings.”
Originally piloted as “Project Scio” last November, FactoryTalk Analytics is now available globally.
About Rockwell Automation
Rockwell Automation Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and information, makes its customers more productive and the world more sustainable. Headquartered in Milwaukee, Wis., Rockwell Automation employs approximately 22,000 people serving customers in more than 80 countries.
FactoryTalk and LISTEN. THINK. SOLVE. are trademarks of Rockwell Automation Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180423005394/en/
Contact:
Rockwell Automation
Paula Puess, 440-646-3806
pdpuess@ra.rockwell.com
or
Padilla
Leonard
Pollard, 612-455-1758
leonard.pollard@padillaco.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom